ClinicalTrials.gg

Program

pumitamig

Also written as “Pumitamig”, “PM8002” and “BNT327”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.

Furthest: phase 3, since May 14, 202434 company-led studies, 32 open or runningCo-development: BioNTech and Bristol Myers Squibb, Jun 2025Next primary completion: Jan 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech2321 open or runningphase 3since May 14, 2024Feb 15, 2023Jan 1, 2027phase 2 · NCT05879055
Bristol-Myers Squibb99 open or runningphase 3since Oct 23, 2025Sep 26, 2024Mar 15, 2028phase 2 · NCT07871214
Boehringer Ingelheim11 open or runningphase 2since Sep 22, 2026Sep 22, 2026Apr 17, 2030phase 2 · NCT07843940
DualityBio11 open or runningphase 2since Apr 9, 2025Apr 9, 2025Jun 30, 2030phase 2 · NCT06953089
  • Named in Bristol-Myers Squibb’s own pipeline as pumitamig, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: MediLink Therapeutics (Suzhou), biontech-shanghai-pharmaceuticals-co-ltd and Genmab.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Feb 15, 2023.

  1. Mar 19, 2025Phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06892548 · 594 planned · United States, Australia, China and more
  2. Apr 9, 2025DualityBio's first study: phase 2 study in Squamous Cell Carcinoma of Head and NeckNew to DualityBioDualityBio · NCT06953089 · 750 planned · United States, Australia, China and more
  3. Jul 3, 20252 phase 2 studiesBioNTech · NCT07070232, NCT07079631
  4. Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBioNTech · NCT07111520 · 880 planned · United States, Australia, China and more
  5. Sep 8, 2025Phase 3 study in Breast NeoplasmsBioNTech · NCT07173751 · 558 planned · United States, Argentina, Australia and more
  6. Oct 23, 20252 phase 3 studiesBristol-Myers Squibb · NCT07221357, NCT07221149
  7. Dec 9, 2025Phase 2 study in GlioblastomaBioNTech · NCT07297212 · 75 planned · China
  8. Dec 17, 20252 phase 2 studiesBristol-Myers Squibb · NCT07293351, NCT07291076
  9. Jan 21, 20262 phase 3 studies in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07361510, NCT07361497
  10. Jun 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07680764 · 160 planned · United States, Argentina, Australia and more
  11. Sep 22, 2026Boehringer Ingelheim's first study: phase 2 study in Small Cell Lung CarcinomaNew to Boehringer IngelheimBoehringer Ingelheim · NCT07843940 · 55 planned · United States, Australia, Belgium and more
  12. Oct 7, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07871214 · 80 planned · United States, Australia, Canada and more
  13. Oct 14, 2026Primary completion moved from 2028-12 to 2029-04Date moved laterphase 3 · +4 months · NCT06712355
  14. Oct 22, 2026Primary completion moved from 2027-01-25 to 2027-05Date moved laterphase 3 · +4 months · NCT06616532

Ahead

  1. Jan 1, 2027Primary completion: phase 2 study in Neuroendocrine TumorsBioNTech · NCT05879055
  2. May 2027Primary completion: phase 3 study in SCLCBioNTech · NCT06616532
  3. Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
  4. Jul 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsBioNTech · NCT06419621

TargetBeta

“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HLX37Fosun Pharmaphase 32

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07871214Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Not yet recruitingBristol-Myers SquibbMar 15, 202880
NCT07843940Small Cell Lung Carcinoma · United States, Australia, Belgium and more2RecruitingBoehringer IngelheimApr 17, 203055
NCT07680764Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2RecruitingBristol-Myers SquibbSep 15, 2028160
NCT07361510Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbOct 14, 2031750
NCT07361497Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbSep 18, 2030850
NCT07293351Carcinoma, Renal Cell · United States, Argentina, Australia and more2RecruitingBristol-Myers SquibbNov 28, 2029474
NCT07291076Carcinoma, Hepatocellular · United States, Australia, Chile and more2RecruitingBristol-Myers SquibbOct 15, 2029198
NCT07297212Glioblastoma · China2RecruitingBioNTechJan 202875
NCT07221357Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbFeb 2, 2030990
NCT07221149Stomach Neoplasms · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbNov 8, 2030690
NCT07173751Breast Neoplasms · United States, Argentina, Australia and more3RecruitingBioNTechDec 2029558
NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more2RecruitingBioNTechNov 2028880
NCT07079631Colorectal Neoplasms · United States, Germany, Japan and more2RecruitingBioNTechDec 2030482
NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more2RecruitingBioNTechMar 20281,438
NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more2RecruitingDualityBioJun 30, 2030750
NCT06892548Small Cell Lung Carcinoma · United States, Australia, China and more2RecruitingBioNTechSep 2028594
NCT06841055Carcinoma, Non-Small-Cell Lung · United States, Australia, South Korea and more2RecruitingBioNTechOct 202860
NCT06827236Breast Neoplasms · United States, Australia, Canada and more2RecruitingBioNTechAug 2029380
NCT06712355Small Cell Lung Carcinoma · United States, Australia, China and more3RecruitingBioNTechApr 2029621
NCT06712316Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBioNTechJan 20291,580
NCT06618287Lung Neoplasms · United States, Australia, Canada and more2RecruitingBristol-Myers SquibbFeb 26, 2031416
NCT06616532SCLC · China3Active, not recruitingBioNTechMay 2027404
NCT06584071Liver Neoplasms2Not yet recruitingBioNTechOct 2026140
NCT06449222Triple Negative Breast Neoplasms · United States, Australia, Turkey (Türkiye) and more2Active, not recruitingBioNTechAug 202883
NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more2Active, not recruitingBioNTechJun 2027110
NCT06419621Triple Negative Breast Neoplasms · China3Active, not recruitingBioNTechJul 2027392
NCT05918133TNBC · China2Active, not recruitingBioNTechOct 30, 202642
NCT05918107MPM · China2CompletedBioNTechMar 31, 202631
NCT05918445Neoplasms · China2RecruitingBioNTechNov 30, 2025380
NCT05879068SCLC · China2Active, not recruitingBioNTechApr 30, 202599
NCT05879055Neuroendocrine Tumors · China2Active, not recruitingBioNTechJan 1, 202731
NCT05864105Carcinoma, Hepatocellular · China2CompletedBioNTechJul 24, 202535
NCT05844150SCLC · China2Active, not recruitingBioNTechMay 10, 202450
NCT05756972NSCLC · China2Active, not recruitingBioNTechSep 13, 202464

How it is read

Names in the registry

  • “Pumitamig”, 18 entries
  • “PM8002”, 11 entries
  • “BNT327”, 3 entries
  • “BNT327 Dose Level 1 (DL1)”, 2 entries
  • “BNT327 Dose Level 2 (DL2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.